Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Operating Leases: 2019-2024

Historic Operating Leases for Agios Pharmaceuticals (AGIO) over the last 6 years, with Dec 2024 value amounting to $40.2 million.

  • Agios Pharmaceuticals' Operating Leases fell 26.83% to $44.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.5 million, marking a year-over-year decrease of 26.83%. This contributed to the annual value of $40.2 million for FY2024, which is 29.45% down from last year.
  • Per Agios Pharmaceuticals' latest filing, its Operating Leases stood at $40.2 million for FY2024, which was down 29.45% from $57.0 million recorded in FY2023.
  • In the past 5 years, Agios Pharmaceuticals' Operating Leases ranged from a high of $97.5 million in FY2020 and a low of $40.2 million during FY2024.
  • For the 3-year period, Agios Pharmaceuticals' Operating Leases averaged around $56.4 million, with its median value being $57.0 million (2023).
  • Data for Agios Pharmaceuticals' Operating Leases shows a maximum YoY declined of 29.45% (in 2024) over the last 5 years.
  • Yearly analysis of 5 years shows Agios Pharmaceuticals' Operating Leases stood at $97.5 million in 2020, then declined by 12.11% to $85.7 million in 2021, then declined by 15.95% to $72.0 million in 2022, then dropped by 20.85% to $57.0 million in 2023, then decreased by 29.45% to $40.2 million in 2024.